Avelumab and Merkel Cell Carcinoma: Therapeutic Mechanism and Safety Considerations
From General Health Literacy to Occupational Exposure Awareness
General health and science communication has long emphasized the importance of understanding how environmental and pharmaceutical exposures influence human biology. This foundational knowledge equips both clinicians and the public to recognize potential risks associated with new therapeutic agents. As medical science advances, the introduction of immunomodulatory drugs such as Avelumab—a PD-L1 inhibitor used in oncology—raises important questions about unintended biological consequences. While such therapies are designed to harness the immune system against malignancies, their mechanism of action may also perturb normal cellular regulation in ways that merit careful scrutiny. In occupational settings, particularly for workers involved in the production, handling, or administration of these biologics, the potential for chronic low-level exposure or accidental contact becomes a relevant concern. The transition from general health literacy to a focused occupational exposure perspective requires acknowledging that even targeted immunotherapies can have off-target effects when encountered outside controlled clinical environments. This shift in viewpoint does not presuppose causation but rather establishes a framework for evaluating whether sustained exposure to Avelumab in manufacturing or healthcare workplaces could contribute to altered immune surveillance or cellular stress responses. Such considerations are essential for developing appropriate monitoring and protective measures in occupational health practice.
Avelumab as a Therapeutic Agent for Merkel Cell Carcinoma
Avelumab (Bavencio) is a fully human IgG1 monoclonal antibody that functions as an immune checkpoint inhibitor by targeting programmed cell death ligand 1 (PD-L1) (https://pubmed.ncbi.nlm.nih.gov/29799096). It was approved in the USA, the EU, and Japan for the treatment of metastatic Merkel cell carcinoma (MCC), making it the first therapeutic agent specifically approved for this indication, independent of line of treatment (https://pubmed.ncbi.nlm.nih.gov/29799096). Approval was based on the two-part, single-arm, phase II JAVELIN Merkel 200 trial, in which confirmed objective responses were observed in approximately one-third of patients with chemotherapy-refractory metastatic MCC (https://pubmed.ncbi.nlm.nih.gov/29799096). Merkel cell carcinoma is a rare and aggressive neuroendocrine cutaneous malignancy with poor prognosis, and in Europe, approved systemic therapies are limited to the PD-L1 inhibitor avelumab (https://pubmed.ncbi.nlm.nih.gov/33439294). Approximately 80% of MCC cases are caused by the human Merkel cell polyomavirus, while the remaining 20% are induced by UV light leading to mutations (https://pubmed.ncbi.nlm.nih.gov/34445385). The standard treatment of metastatic MCC includes anti-PD-1/-PD-L1 immune checkpoint inhibitors such as avelumab, which show better overall response rates and longer duration of responses compared with conventional chemotherapy (https://pubmed.ncbi.nlm.nih.gov/34445385). Nevertheless, 50% of patients do not respond or develop immune-related adverse events (irAEs) due to diverse mechanisms, such as down-regulation of MHC complexes or the induction of anti-inflammatory cytokines (https://pubmed.ncbi.nlm.nih.gov/34445385).
Mechanism of Action and Immune-Related Adverse Events
The pathophysiology linking avelumab to Merkel cell carcinoma involves its mechanism as an immune checkpoint inhibitor. Avelumab blocks PD-L1, thereby preventing the interaction between PD-L1 on tumor cells and PD-1 on T cells, which normally suppresses T-cell activity. This blockade enhances T-cell-mediated antitumor immune responses. However, checkpoint inhibitors including avelumab are known to cause overactivation of the immune system, leading to immune-related adverse events (https://pubmed.ncbi.nlm.nih.gov/31543781). In the context of MCC, avelumab is used therapeutically to treat the disease, not to trigger it. The evidence indicates that avelumab is an approved treatment for metastatic MCC, and its use is associated with improved outcomes in a subset of patients. For avelumab-refractory patients, efficient and safe treatment options are lacking, though combined ipilimumab plus nivolumab has shown activity in avelumab-refractory MCC in a small multicenter study (https://pubmed.ncbi.nlm.nih.gov/33439294). In that study, three out of five patients responded to combined IPI/NIVO according to RECIST 1.1 (https://pubmed.ncbi.nlm.nih.gov/33439294). Another multicenter study of the prospective skin cancer registry ADOREG reported that immune checkpoint inhibition has significantly improved treatment outcomes in metastatic disease, with response rates to PD-1/PD-L1 inhibition of up to 62% (https://pubmed.ncbi.nlm.nih.gov/36450381).
Causation and Risk Considerations
Regarding causation-related considerations, the timeline between avelumab exposure and documented harm is relevant for patients who experience adverse events. A case report described hypercalcaemia due to sarcoidosis during treatment with avelumab for metastatic MCC, which was managed with corticosteroids to full resolution, and avelumab therapy was safely continued (https://pubmed.ncbi.nlm.nih.gov/31543781). This illustrates that immune-related adverse events can occur during treatment, but they are typically manageable and do not necessarily indicate that avelumab triggers MCC pathophysiology. Instead, avelumab is used to treat MCC, and its adverse effects are related to immune overactivation rather than causing the disease itself. Risk anchors include the adequacy of warnings regarding avelumab and Merkel cell carcinoma. The evidence shows that avelumab is approved specifically for metastatic MCC, and its prescribing information includes warnings about immune-related adverse events. However, the query asks about how avelumab triggers MCC pathophysiology, which is not supported by the evidence. Avelumab is a treatment for MCC, not a trigger. The evidence does not indicate that avelumab causes or triggers Merkel cell carcinoma; rather, it is used to treat the condition. For affected patients, the primary causation consideration is that avelumab is administered to patients who already have MCC, and any harm from the drug is related to adverse effects, not to inducing the disease. The timeline between exposure and documented harm is typically during or after treatment, as seen in the case of hypercalcaemia due to sarcoidosis (https://pubmed.ncbi.nlm.nih.gov/31543781). In summary, the evidence supports that avelumab is an effective treatment for metastatic MCC, with response rates of approximately one-third in chemotherapy-refractory patients and up to 62% in broader populations. The drug functions by blocking PD-L1 to enhance antitumor immunity, but it can cause immune-related adverse events. There is no evidence that avelumab triggers MCC pathophysiology; instead, it is used to treat the disease. Warnings about adverse events are standard for immune checkpoint inhibitors, and the risk for patients is primarily related to irAEs rather than causation of MCC.
Important Notice
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
Community Resource & Benefit Desk
Request archival records or inquire about member-exclusive transition and benefit programs.
Frequently Asked Questions
Does avelumab cause Merkel cell carcinoma?
No, avelumab is a treatment for Merkel cell carcinoma (MCC), not a cause. It is an immune checkpoint inhibitor approved for metastatic MCC and works by blocking PD-L1 to enhance antitumor immunity. There is no evidence that avelumab triggers MCC pathophysiology; instead, it is used to treat the disease.
What are the common side effects of avelumab?
Avelumab can cause immune-related adverse events (irAEs) due to overactivation of the immune system. These may include conditions like hypercalcaemia due to sarcoidosis, as reported in a case study (https://pubmed.ncbi.nlm.nih.gov/31543781). Other irAEs are typical for checkpoint inhibitors and are manageable with appropriate medical intervention.
How effective is avelumab for Merkel cell carcinoma?
Free and confidential. No obligation — an initial records screening only.
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.